Edition:
India

People: BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

5.80USD
17 Oct 2019
Change (% chg)

$-0.43 (-6.90%)
Prev Close
$6.23
Open
$6.20
Day's High
$6.39
Day's Low
$5.79
Volume
25,551
Avg. Vol
18,555
52-wk High
$12.00
52-wk Low
$2.41

Mehta, Vimal 

Mr. Vimal Mehta, Ph.D. is the President, Chief Executive Officer, Secretary, and Director of the Company. He is a co-founder of BioXcel Corporation and has served as its Chairman of the Board since 2005 and its Chief Executive Officer since September 2014. Dr. Mehta has held various senior scientific and business development positions, including Senior Vice President of Business Development at London-based Inpharmatica Ltd, a global predictive informatics company, from 2002 to 2006 and Senior Vice President, Business Development for Jubilant Life Sciences, an integrated global pharmaceutical and life sciences company, from 2006 to 2007. Previously, Dr. Mehta served as Business Development Manager at CuraGen Corporation, a biotechnology company, from 1996 to 2002. He held multiple positions in the Department of Radiology at the University of Texas, Southwestern Medical Center from 1989 to 1996, including Postdoctoral Fellow, Instructor and Assistant Professor. Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr. Mehta has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives encompassing corporate strategy and planning, global business development, and corporate fundraising. He has helped to shape the company's strategic and business trajectory which the Board believes qualifies him to serve as a director of our company.

Basic Compensation

Total Annual Compensation, USD 693,359
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 8,250
Fiscal Year Total, USD 701,609

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --